SCR7 pyrazine 10 mg | 99.83%
TargetMol
Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
More Information Supplier PageSCR7 pyrazine
Search Results
SCR7 pyrazine 25 mg | 99.83%
TargetMol
Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
More Information Supplier PageSCR7 pyrazine
SCR7 pyrazine 50 mg | 99.83%
TargetMol
Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
More Information Supplier PageSCR7 pyrazine
SCR7 pyrazine 5 mg | 99.83%
TargetMol
Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
More Information Supplier PageSCR7 pyrazine
WZ811 100 mg | 99.93%
TargetMol
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
More Information Supplier PageWZ811
WZ811 10 mg | 99.93%
TargetMol
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
More Information Supplier PageWZ811
TBPB 50 mg | Purity Not Available
TargetMol
TBPB
TBPB 25 mg | Purity Not Available
TargetMol
TBPB
TBPB 10 mg | Purity Not Available
TargetMol
TBPB
WZ811 5 mg | 99.93%
TargetMol
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
More Information Supplier PageWZ811